|1.||Federici, Massimo: 8 articles (10/2015 - 12/2005)|
|2.||Khokha, Rama: 8 articles (08/2011 - 10/2004)|
|3.||Rey, Juan A: 8 articles (02/2006 - 03/2003)|
|4.||Bello, M Josefa: 8 articles (02/2006 - 03/2003)|
|5.||Menghini, Rossella: 7 articles (10/2015 - 12/2005)|
|6.||Khokha, R: 7 articles (07/2015 - 03/2001)|
|7.||Li, Ren-Ke: 7 articles (01/2014 - 02/2003)|
|8.||Baker, Andrew H: 7 articles (01/2013 - 01/2002)|
|9.||Lauro, Renato: 7 articles (11/2012 - 12/2005)|
|10.||Gonzalez-Gomez, Pilar: 7 articles (11/2004 - 03/2003)|
01/01/2012 - "Inhibiting matrix metalloproteinase by cell-based timp-3 gene transfer effectively treats acute and chronic ischemic cardiomyopathy."
05/01/2014 - "TIMP-3 is highly expressed in the heart and is markedly downregulated in patients with ischaemic cardiomyopathy. "
11/01/2014 - "Gel-released TIMP-1 and TIMP-3 significantly improved cardiac function and myocardial remodeling and enhanced SMA expression in the infarcted area in ischemic cardiomyopathy model rats. "
07/01/2007 - "In conclusion, chronic doxorubicin cardiomyopathy was characterized by increased MMP and decreased TIMP-3 expression. "
12/15/2006 - "Amelioration of hepatic ischemia/reperfusion injury after inhibition of TACE activity by TIMP-3 suggests that TACE inhibition may play an important role in preventing liver ischemia/reperfusion injury warranting further experimental and clinical study."
11/01/2002 - "Tissue inhibitor of metalloproteinase-3 is associated with neuronal death in reperfusion injury."
12/15/2006 - "TIMP-3 ameliorates hepatic ischemia/reperfusion injury through inhibition of tumor necrosis factor-alpha-converting enzyme activity in rats."
05/01/2011 - "TIMP-3 deficiency resulted in a fourfold increase in cardiac rupture and 50% decrease in survival after MI. "
05/01/2011 - "Treatment with cetuximab significantly decreased the incidence of cardiac rupture and improved survival post-MI in TIMP-3(-/-) mice. "
05/01/2011 - "Deficiency in TIMP-3 increases cardiac rupture and mortality post-myocardial infarction via EGFR signaling: beneficial effects of cetuximab."
05/01/2011 - "We conclude that deficiency in TIMP-3 increases cardiac rupture post-MI via EGF/epidermal growth factor receptor (EGFR) signaling which downregulates TGF-β1 expression and collagen synthesis. "
05/01/2011 - "This study investigated the role of tissue inhibitor of metalloproteinase-3 (TIMP-3)/matrix metalloproteinase (MMP)/epidermal growth factor (EGF)/transforming growth factor (TGF)-β1 pathway in infarct healing and effects of cetuximab on cardiac rupture after MI. "
|4.||Ovarian Neoplasms (Ovarian Cancer)
07/01/2008 - "AGTR2 treatment was found to be more effective in inhibiting ovarian cancer growth than the treatment with TIMP-3 in parallel experiments. "
03/08/2007 - "Our data indicate that inactivation of TIMP-3 by somatic mutation or promoter hypermethylation is rare in ovarian cancer."
03/08/2007 - "We analyzed 65 ovarian cancers for both somatic genetic mutations and TIMP-3 promoter hypermethylation. "
03/08/2007 - "TIMP-3 has not previously been investigated for somatic mutations or promoter hypermethylation in ovarian cancer. "
03/08/2007 - "Genetic and epigenetic analysis of the TIMP-3 gene in ovarian cancer."
|1.||Tissue Inhibitor of Metalloproteinase-1
|2.||tumor necrosis factor-alpha convertase
|4.||Tissue Inhibitor of Metalloproteinase-3
|5.||Messenger RNA (mRNA)
|7.||Tissue Inhibitor of Metalloproteinase-2
|9.||Tissue Inhibitor of Metalloproteinases (TIMP)
|1.||Transplantation (Transplant Recipients)
|3.||Artificial Respiration (Mechanical Ventilation)
|4.||Heterologous Transplantation (Xenotransplantation)